Keywords
enteropathy
celiac disease
refractory celiac disease
How to Cite
Abstract
Enteropathy-associated T-cell lymphoma is a rare and aggressive type of peripheral T-cell lymphoma, frequently associated with celiac disease. Refractory celiac disease (RCD), the main cause of lack of response to the diet may be developed after the inadvertent and prolonged ingestion of gluten. Two types of RCD are recognized: type I and type II, while type II is currently considered a pre-lymphomatous state. The persistence of an inflammatory stimulus posed by the continuous intake of gluten in celiac patients determine a disturbance of intestinal lymphocyte homeostasis, raising the possibility to evolve to a lymphoma. The target of malignant transformation appears to be an intraepithelial lymphocyte developing increased proliferation potential and apoptosis escape. A 62-year-old male case is presented as illustration of the possible relationship between these two entities as the mechanisms intertwined between.
References
Di Sabatino A, Biagi F, Gobbi P et al, How I treat enteropathy-associated T-cell lymphoma. Blood. 2012;119: 2458-68. https://doi.org/10.1182/blood-2011-10-385559.
Azzam S, Goa P, Vandenberghe E et al. Update on the Pathogenesis of Enteropathy-Associated T-Cell Lymphoma. Diagnostics. 2023; 13: 2629. https://doi.org/10.3390/diagnostics13162629.
Chander U, Leeman-Neil R, Bhagat G. Pathogenesis of Enteropathy-Associated T Cell Lymphoma. Current Hematologic Malignancy Reports. 2018; 13: 308-317. https://doi.org/10.1007/s11899-018-0459-5.
De Leval L, Bisig B. What is new in the classification of peripheral T cell lymphomas? Pathologie. 2023; 44: 128-135. https://doi.org/10.1007/s00292-023-01260-y.
Busto V, Crespo L, Rodríguez-Gandía M et al. Linfoma T asociado a enteropatía: un reto diagnóstico. Gastroenterol Hepatol. 2011; 34: 686-689. https://doi:10.1016/j.gastrohep-2011.08.004.
Al Somali Z, Hamadani M, Kharfan-Dabaja M et al. Enteropathpy-Associated T cell Lymphoma. Curr Hematol Malig Rep. 2021; 16:140-147. https://doi.org/10.1007/s11899-021-00634-4.
Nijeboer P, R. de Baaij L, Visser O et al. Treatment response in enteropathy associated T-cell lymphoma; survival in a large multicenter cohort. Am J Hematol. 2015; 90: 493-8. https://doi.org/10.1002/ajh.23992.
Meresse B, Ripoche J, Heyman M et al. Celiac disease: from oral tolerance to intestinal inflammation, autoimmunity and lymphomagenesis. Mucosal Immunol. 2009; 2:8-23. https://doi: 10.1038/mi.2008.75.
Ma H, Qiu Y, Yang H. Intestinal intraepithelial lymphocytes: Maintainers of intestinal immune tolerance and regulators of intestinal immunity. J Leukoc Biol. 2021; 109: 339-347. https:// doi: 10.1002/JLB.3RU0220-111.
McDonald B, Jabri B, Bendelac A. Diverse developmental pathways of intestinal intraepithelial lymphocytes. Nat Rev Immunol. 2018; 18:514-525. https://doi.org/10.1038/s41577-018-0013-7.
Zhang J, Wang Y, Wang X et al. Type I enteropathy-associated T-cell lymphoma in the colon of a 29-yearold patient and a brief literature review. Onco Targets Ther. 2016; 22:863-868. https://doi: 10.2147/OTT.S96745.
Delabie J, Holte H, Vose J et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. Blood. 2011; 118:148–155. https://doi.org/10.1182/blood-2011-02-335216.
Scarmozzino F, Pizzi M, Pelizzaro F et al. Refractory celiac disease and its mimickers: a review on pathogenesis, clinical-pathological features and therapeutic challenges. Front Oncol. 2023; 13:1273305. https://doi.org/10.3389/fonc.2023.1273305.
Vaquero L, Alvarado M, Arias L et al, Linfoma intestinal de células T asociado a enteropatía y sin relación con enfermedad celíaca. Gastroenterol Hepatol. 2012; 35:17-21. https://doi.org/10.1016/j.gastrohep.2011.11.003.
Moscoso F, Quera R. Update on celiac disease. Rev. Méd. Chile. 2016; 144:2, https://doi.org/10.4067/S0034-98872016000200010.
Freedman A, Aster J. (2022). Clinical manifestations. Pathologic features, and diagnosis of enteropathy-associated T cell lymphoma. Lister A, Rosmarin A (Ed.), UpToDate.
Nijeboer P, Malamut G, Mulder C et al. Enteropathy- Associated T-Cell Lymphoma: Improving Treatment Strategies. Digestive Diseases. 2015; 33:231-235. https://doi.org/10.1159/000369542.
Khalaf W, Caldwell M, Reddy N. Brentuximab in the Treatment of CD30-Positive Enteropathy-Associated T-Cell Lymphoma. Journal of the National Comprehensive Cancer Network. 2013; 11:137-140.
Sibon D, Khater S, Bruneau J et al. The Eatl-001 Trial: Results of a Phase 2 Study of Brentuximab Vedotin and CHP Followed By Consolidation with High- Dose Therapy - Autologous Stem-Cell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-Cell Lymphoma. Blood. 2021; 138:136. https://doi.org/10.1182/blood-2021-153709.
Sieniawski M, Angamuthu N, Boyd K et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel régimen including autologous stem cell transplantation. Blood. 2010;115(18):3664-3670. https://doi.org/10.1182/blood-2009-07-231324.
Jantunen E, Boumendil A, Finel H et al. Autologous Stem Cell Transplantation (ASCT) for Enteropathy- Associated T-Cell Lymphoma (EATL): Final Analysis of a Retrospective Study On the Behalf of Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2012; 120:3105. https://doi.org/10.1182/blood. V120.21.3105.3105.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar